Colorado Springs teacher selected for VFW Top Award
(COLORADO) — A middle school teacher from Colorado Springs has been selected to receive a 2025 Smart/Maher VFW National Citizenship Education Teacher Award.
Christie Wingo, a middle school science, technology, engineering, and math teacher at Colorado Springs Christian School, was selected to receive the award at the middle-school level. Each year, the Veterans of Foreign Wars (VFW) selects elementary, middle, and high school teachers to participate in the Smart/Maher VFW National Citizenship Education Teacher program.
The program was launched by the VFW to recognize classroom teachers for their 'outstanding' commitment to teaching Americanism and patriotism to their students.
Wingo was sponsored by VFW Post 7829 in Monument. According to the VFW, Wingo 'was chosen for her continued efforts to prepare responsible citizens while encouraging a strong passion for STEM and fostering an atmosphere that values hard work, collaboration, and bettering their community.'
As a member of the Space Foundation's International Teacher Liaisons Group, Wingo uses space-related educational programs and practical resources in the classroom. Wingo also works to bolster education on cybersecurity, biomedical engineering, machine learning, and robotics.
Wingo is also working on bringing hands-on projects to the school to further inspire her students.
'The VFW is proud to recognize outstanding educators like Christie who inspire civic responsibility and patriotism in our youth, ensuring the pillars of our democracy are not forgotten,' said VFW National Commander Al Lipphardt. 'Beyond academics, she inspires critical thinking, a deep respect for democracy, and helps foster curiosity. Her influence extends far beyond the classroom, helping to cultivate a generation that values integrity, civic duty, and the power of informed decision-making — essential qualities for those who will guide our nation forward.'
Two other teachers from Illinois and New Jersey were also recognized. Wingo and the other two national recipients will be presented with a $1,000 award for professional development and $1,000 for their school during the 126th VFW National Convention in Ohio on Aug. 9-13.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Doctor mistakenly implants wrong embryo in IVF patient mix-up
One of Australia's top IVF providers mistakenly implanted a patient with her own embryo instead of her partner's. Monash IVF said the incident occurred on June 5 at a clinic in Melbourne but did not provide further details, such as how it learned of the bungle or what the couple planned to do next. The company said it was supporting the couple, who it did not identify. It marks the second fertility clinic mix-up of its kind in the country, heightening concerns about an industry that did not have much active government oversight until recently. The clinic said the patient's embryo was mistakenly implanted under a treatment plan which called for an embryo from the patient's partner to be transferred. The incident builds on a reputational maelstrom for Monash IVF, which was already reeling from an April disclosure that an Australian woman had given birth to a stranger's baby after a fertility doctor accidentally implanted the wrong embryo in Brisbane in 2023. That mix-up sparked concerns about security protocols at IVF clinics and an industry which is only now in the process of being more regulated. Monash claimed the world's first IVF pregnancy five decades ago and is Australia's second-largest IVF provider, carrying out nearly a quarter of the country's 100,000 assisted reproductive cycles a year, according to industry data. "This mix-up, the second reported incident at Monash IVF, risks shaking confidence not just in one provider but across the entire fertility sector," said Hilary Bowman-Smart, a researcher and bioethicist at the University of South Australia. Shares of Monash IVF were down 25 per cent by mid-session on Tuesday, against a rising broader market. The stock is just over half its value before the April announcement. "We had thought the Brisbane clinic embryo transfer error was an isolated incident," Craig Wong-Pan, an analyst at RBC Capital Markets, said in a client note. "We believe there is now risk of a greater impact of reputational damage and market share losses to MVF's operations." Monash IVF had already hired a lawyer to run an independent investigation after the Brisbane incident, and said on Tuesday it has extended the scope of that investigation. It added that it was installing interim extra verification safeguards to ensure patient confidence. It said it had reported the Melbourne incident to the Victorian Department of Health and industry licensing body, the Reproductive Technology Accreditation Committee (RTAC), part of industry group the Fertility Society of Australia. Victorian health minister Mary-Anne Thomas said the department was investigating the company and the incident. "Families should have confidence that the treatment they are receiving is done to the highest standard," she said. "It is clear Monash IVF has failed to deliver that, which is completely unacceptable." Fertility Society president Petra Wale said the incident would have had an emotional toll on the family, but stressed mistakes in the sector were rare. The society reiterated a call to implement nationally consistent laws around IVF. Currently, the country's IVF industry is regulated by a combination of industry bodies and state and territory health departments, resulting in a governance and compliance system that some groups say is too complex. Reports of transferring the wrong embryo are rare, according to fertility experts, and Monash's Brisbane mix-up was widely reported as the first known case of its kind.
Yahoo
6 days ago
- Yahoo
ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
UNIONDALE, NY, June 06, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the 'Company' or 'ProPhase') a next generation biotech, genomics and consumer products company, today announced the formation of its Clinical Science Advisory Board to support the clinical adoption and commercialization of its breakthrough BE-SmartTM molecular test for esophageal disease. The advisory board will provide expert strategic guidance as ProPhase leads the regulatory and commercialization pathway for BE-Smart, with the goal of establishing a new clinical and economic standard in the early detection and management of esophageal cancer risk. A full data package detailing the test's validation and clinical utility is currently under peer review. The advisory board includes Dr. Joe Abdo, the inventor of the BE-Smart test and a nationally recognized leader in molecular oncology. Dr. Abdo looks to leverage his deep relationships with academia, the Mayo Clinic GI Path department, KUMC gastroenterology and KOLs in the esophageal cancer space. Also joining the advisory board is Mr. James McCullough, founder and CEO of Renalytix and former Chief Executive Officer of Exosome Diagnostics Inc., a pioneer in liquid biopsy diagnostics. Additional key opinion leaders and experts in the field will be added to the advisory board in the near future as the Company plans for its initial commercial launch. 'We believe BE-Smart has the potential to redefine how some severe esophageal disease progressing to cancer is detected and managed,' said Ted Karkus, Chief Executive Officer of ProPhase Labs. 'This advisory board brings together the scientific leadership, clinical insight, and operational expertise needed to scale this innovation and bring it into widespread clinical use. It's a major step toward realizing the full value of BE-Smart for patients, physicians, and payers. Our target market is roughly 7 million endoscopies performed each year in the United States alone on patients at risk of esophageal cancer, with a reimbursement goal of $1,000 - $2,000 per test. This equates to a $7 - $14 billion target market that is virtually untapped. We believe that our test will significantly enhance the accuracy of the endoscopy, which will in turn save thousands of lives and save the insurance companies billions of dollars.' BE-Smart offers a distinct advantage in the molecular diagnostics landscape for esophageal disease. Unlike imaging-based or DNA methylation approaches, BE-Smart measures real-time protein activity, capturing the dynamic biological signals of disease progression. It requires only a single 10 µm FFPE biopsy section, minimizing tissue burden and simplifying lab workflows. The test integrates seamlessly into existing endoscopy and pathology procedures, delivering results in under 7 days with no added complexity for providers. Its versatility extends beyond progression prediction. BE-Smart can help stratify risk across a spectrum of patients with GERD and Barrett's Esophagus, including those with non-dysplastic or indefinite dysplasia, areas where current tools often fall short. This broad clinical utility, coupled with its scalable, cost-efficient design, makes BE-Smart a compelling option for both frontline clinicians and healthcare systems aiming to optimize care pathways and reduce unnecessary interventions. While other technologies like TissueCypher (Castle Bioscience) and EsoGuard (Lucid Diagnostics) have established early momentum in the esophageal diagnostics space, each has helped pave the way for broader adoption of molecular tools in GI practice. TissueCypher has been instrumental in introducing pathologists and gastroenterologists to the value of tissue-based molecular insights, while EsoGuard's less invasive disease monitoring method shows potential to expand the addressable patient population and encourage earlier engagement. BE-Smart builds on this progress by offering a next-generation approach that combines real-time biological precision with streamlined clinical integration. Its high-throughput, multiplexible design, enabled by advanced mass spectrometry, allows for deep protein-level analysis from minimal tissue input, positioning it to deliver both depth of insight and operational ease across a wide range of care settings. The BE-Smart molecular test is strengthened by robust intellectual property protection centered on eight key proteins identified as critical biomarkers for esophageal adenocarcinoma progression. ProPhase Labs, Inc. has secured exclusive patents covering the proprietary methods for detecting and analyzing the expression of these proteins, which are uniquely associated with the molecular mechanisms driving this esophageal disease and its progression to malignancy. This IP portfolio not only safeguards the innovative approach of BE-Smart in measuring real-time protein activity through advanced mass spectrometry but also establishes a significant competitive advantage in the molecular diagnostics market. The latest BE-Smart clinical validation manuscript, "Assessing Risk of Progression in Barrett's Esophagus Using a Mass-Spectrometry-Based Proteomic Panel" is under review at the Journal of Clinical Gastroenterology and Hepatology. A preprint may be available in the coming weeks. Dr. Joe Abdo is a molecular oncology scientist with over 15 years of experience in cancer diagnostics, translational research, and biotech business development. He has held leadership roles across public and private biotechnology companies, with a focus on early cancer detection, immunotherapy response prediction, and clinical utility studies. He has authored more than 30 peer-reviewed publications and teaches graduate-level courses at Georgetown University Medical Center. Mr. James McCullough brings decades of leadership experience in precision medicine, having successfully launched and scaled diagnostic technologies in both the public and private sectors. The Clinical Science Advisory Board will focus on accelerating clinical adoption, guiding payer education, and supporting evidence development and regulatory advancement. About ProPhase Labs Inc. ProPhase Labs Inc. (Nasdaq: PRPH) ('ProPhase') is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs' valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. Media Relations and Institutional Investor Contact: ProPhase Labs, Retail Investor Relations Contact: Renmark Financial CommunicationsJohn Boidman: jboidman@ (416) 644-2020 or (212)
Business Wire
02-05-2025
- Business Wire
Gemelli Biotech's Innovative Trio-Smart® Breath Test Featured in Multiple Research Studies at DDW 2025
RALEIGH, N.C.--(BUSINESS WIRE)--Gemelli Biotech and its technologies will be featured in several presentations at Digestive Disease Week® (DDW) 2025. These studies used Trio-Smart®, a diagnostic 3-gas breath test developed and distributed by Gemelli Biotech that uniquely detects hydrogen sulfide, in addition to hydrogen and methane. 'We're excited to see Trio-Smart contributing to research that can help millions of people who suffer from the symptoms of IBS." Share The studies further validates the accuracy and utility of Trio-Smart and shows the significant cost savings that can result from its use in the diagnosis of SIBO (small intestinal bacterial overgrowth). Research being presented includes: An Integrative Approach to Improve 3-Gas Breath Tests Using Patient Symptom Profile by Machine Learning (5/3/25 12:30-1:30pm POSTER #Sa2030) Real World Study of Three-Gas Breath Testing Nationwide and the Association With Symptoms (5/5/25 12:30-1:30pm POSTER #Mo1405) Lactulose Breath Testing Is More Often Positive and Associated With Symptoms Compared to Glucose in a Nationwide Study of Kit-Based Three-Gas Breathing (5/6/25 12:30-1:30pm POSTER #Tu2015) Low- And High-Dose Rifaximin Versus Low-Dose Rifaximin Combined With N-Acetylcysteine For Treating Diarrhea-Predominant Irritable Bowel Syndrome: A Double-Blind, Randomized Proof-Of-Concept Trial (5/5/25 4:00pm Session #4585, ROOM 24 (SDCC) Matt Mitcho, CEO of Gemelli Biotech, said 'Our understanding of the gut microbiome has grown dramatically, largely driven by access to new and better research tools. Studies like these have never been done with breath testing for chronic GI complaints. They emphasize the validity and importance of measuring all three gases during breath testing.' He also explained that, 'We're excited to see Trio-Smart contributing to research that can help millions of people who suffer from the symptoms of IBS. Our unique ability to detect hydrogen sulfide coupled with our high-precision hydrogen and methane measurement makes Trio-Smart a powerful research tool. We have been talking with oncologists and other researchers about using our breath test in the lab and have even heard from rheumatologists and other inflammation-focused researchers about our blood test for markers of post-infectious IBS.' Matt continued, 'We look forward to continuing our ongoing work with the Medically Associated Science and Technology (MAST) program at Cedars-Sinai and to contributing to research in other areas as well.' About Gemelli Biotech Gemelli Biotech develops and distributes at-home, mail-in precision diagnostics for diseases of the gut microbiome. Our mission is to leverage leading biological discoveries related to the microbiome to provide non-invasive, easy-to-understand diagnostics. This enables clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including IBS, SIBO, IMO, and ISO. Our products include the Trio-Smart® breath test that measures levels of hydrogen, methane, and hydrogen sulfide; the IBS-Smart® blood test that measures validated biomarkers of IBS, anti-CdtB, and anti-vinculin, offering a positive diagnostic strategy for patients with IBS symptoms; and the Trio-Smart Malabsorption breath test that helps identify carbohydrate intolerances after lactose, fructose, or sucrose consumption.
